American Association for Cancer Research

Skip to Main Content

Table 3

Protection against BSO-enhanced chemotherapy-induced myelosuppression

The mean and SE are shown for nadir blood counts as a percentage of baseline.
Treatment	No. of rats	White cell nadir (%)	Granulocyte nadir (%)	Platelet nadir (%)
No protectant	11	12.9 ± 3.5	3.5 ± 1.3	9.1 ± 2.3
NAC aortic infusion postchemotherapy	7	13.9 ± 4.2	19.8 ± 14.7	11.7 ± 3.5
NAC aortic infusion 30 min prior to chemotherapy	9	20.1 ± 2.7	115.4 ± 68.8^a	23.1 ± 6.2
NAC aortic infusion 30 min prior + STS postchemotherapy	7	30.5 ± 6.5^a	121.0 ± 40.2^a	39.0 ± 7.4^a

The mean and SE are shown for nadir blood counts as a percentage of baseline.
Treatment	No. of rats	White cell nadir (%)	Granulocyte nadir (%)	Platelet nadir (%)
No protectant	11	12.9 ± 3.5	3.5 ± 1.3	9.1 ± 2.3
NAC aortic infusion postchemotherapy	7	13.9 ± 4.2	19.8 ± 14.7	11.7 ± 3.5
NAC aortic infusion 30 min prior to chemotherapy	9	20.1 ± 2.7	115.4 ± 68.8^a	23.1 ± 6.2
NAC aortic infusion 30 min prior + STS postchemotherapy	7	30.5 ± 6.5^a	121.0 ± 40.2^a	39.0 ± 7.4^a

P < 0.05 compared with no protectant by Wilcoxon/Kruskal-Wallis rank-sums test.